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Abstract
Poor micturition control may cause profound distress, because proper voiding is mandatory
for an active social life. Micturition results from the subtle interplay of central and peripheral
components. It involves the coordination of autonomic and neuromuscular activity at the
brainstem level, under the executive control of the prefrontal cortex. We tested the hypothe-
sis that administration of molecules acting as reuptake inhibitors of serotonin, noradrenaline
or both may exert a strong effect on the control of urine release, in a mouse model of overac-
tive bladder. Mice were injected with cyclophosphamide (40 mg/kg), to increase micturition
acts. Mice were then given one of four molecules: the serotonin reuptake inhibitor imipra-
mine, its metabolite desipramine that acts on noradrenaline reuptake, the serotonin and nor-
adrenaline reuptake inhibitor duloxetine or its active metabolite 4-hydroxy-duloxetine.
Cyclophosphamide increased urine release without inducing overt toxicity or inflammation,
except for increase in urothelium thickness. All the antidepressants were able to decrease
the cyclophosphamide effects, as apparent from longer latency to the first micturition act,
decreased number of urine spots and volume of released urine. These results suggest that
serotonin and noradrenaline reuptake inhibitors exert a strong and effective modulatory ef-
fect on the control of urine release and prompt to additional studies on their central effects
on brain areas involved in the social and behavioral control of micturition.
Introduction
Micturition disorders cause profound distress and may involve central and peripheral mecha-
nisms. An imbalance in noradrenaline and serotonin is involved in both components: reuptake
inhibitors of these neurotransmitters may improve micturition control, although urinary hesi-
tancy and retention are side effects of antidepressant administration [1, 2].
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The storage and release of urine are complex functions necessary for both survival and so-
cially appropriate interactions. They require a complex coordination of incoming sensory in-
puts and descending cortical modulation in pontine centers. Coordination is necessary to
finely tune the autonomic activity directed to bladder and urethra, via sympathetic and para-
sympathetic nerves, and the lumbosacral motoneurons directed to striated sphincters and mus-
cles of the pelvic floor [3]. The activity in motoneurons of Onuf’s nucleus is modulated by both
serotonin and noradrenaline, which facilitate glutamatergic activation and hence prevent acci-
dental bladder voiding when increasing abdominal pressure [4]. Serotonin facilitates the sym-
pathetic storage reflex, while inhibiting the parasympathetic voiding activity.
Imipramine, a serotonin reuptake inhibitor, was the first tricyclic drug used for the treat-
ment of incontinence. Because of its sympathomimetic and anticholinergic properties, it may
decrease the bladder contractility, by acting also as antagonist on muscarinic receptors [5,6].
Moreover, it increases striated urethral sphincter contractions [7]. Imipramine is readily me-
tabolized to its main active metabolite, desipramine, which acts as a selective noradrenaline re-
uptake inhibitor. Therefore, clinical effects of imipramine involve two main actions, on
serotonin and noradrenaline reuptake.
Duloxetine is a reuptake inhibitor for both serotonin and noradrenaline [8, 9]. It was the
first drug licensed for stress incontinence in 2004 in the European Union, due to its ability to
increase bladder capacity and activity in sphincters. Noteworthy, it has no effect on bladder
contractile activity during micturition, because its action is only possible in combination with
glutamatergic excitation [10]. Its patent protection terminated recently, making it a cost-
effective therapeutic option under specific circumstances [11].
The aim of the present work is to test the efficacy of two clinically used tricyclic molecules
(imipramine and duloxetine) and their main metabolites (desipramine and 4-hydroxy-
duloxetine, respectively) on an animal model of overactive bladder (OAB), induced in an out-
bred mouse strain. We stimulated bladder overactivity by injecting cyclophosphamide in CD-1
mice, and showed that this can reliably induce an increase in micturition. We then evaluated
micturition performance after administering one of four antidepressant molecules: all of them
acted by reducing micturition acts, without inducing overt sign of toxicity in the urothelium.
Materials and Methods
Pharmacological treatments and behavioral studies
All experiments were carried out in strict accordance with the European law (EU Directive
2010/63/EU) on animal experiments and welfare, and were approved by the competent author-
ities (local ethical committee and Italian Ministry of Health permit number: 97/2008B-77–08).
All efforts were made to minimize discomfort. Mice were kept at 24±1°C, 60% humidity, 12:12
hours light on starting at 6:00 a.m., with mouse food chow (Altromin, Rieper, Bolzano, Italy)
and water always available. The same experimenter blind to experimental condition performed
all the procedures in the same room. The cyclophosphamide (CYP) OAB model implemented
in C57 inbred mice by Boudes and colleagues [12] was validated in outbred CD1 mouse strain
by treating seven four-month old male mice (4 i.p. injections 40 mg/kg CYP, one every 48
hours; according to [12]) and five controls with saline (9 g/L NaCl, same time schedule). The
CYP dosage was the lowest that increased micturition without altering diuresis [12]. The CD-1
strain was used because its micturition behaviour under various physiological conditions has
been already described [13]. The voiding pattern (latency to the first micturition, number of
droplets, and urine spot area) was simultaneously measured 24 hours after the last CYP injec-
tion at 4:00 p.m. Each mouse was put for 30 minutes in a cage (20x27x18 cm) with the floor
covered with a paper sheet lined with plastic film (BenchGuard cat°BG60E) to retain all urine
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drops. The papers were dried for 48 hours at room temperature, then transilluminated with a
UV source to highlight the urine spots and the images were acquired with a digital camera.
ImageJ software (version 1.47, NIH, USA) was used to count the number of pixels within the
perimeter of each urine spot [14], which was then converted into urine volume (see S1 Fig.).
Subsequently, the effects of four different molecules were tested in the OAB model (see S2
Fig.): imipramine 20 mg/kg [15], desipramine 20 mg/kg [16], duloxetine 2 mg/kg [17] and its
metabolite 4-hydroxy-duloxetine 2 mg/kg [18, 19]. For two consecutive days, starting 24 hours
after the last CYP injection, OAB induced mice (n = 35 CD1 males, 4 month old, 7 in each
group, mean body weight 50.9 ± 0.46 g at the beginning of the treatment, and 51.3 ± 0.37 g at
sacrifice) were injected i.p. with saline as control, or with one of the molecules in 100 μl saline.
Their voiding pattern was monitored for three days: 24 hours after the last CYP injection but
before the antidepressant injection (T0), 24 hours later but before the second treatment (T24),
and 24 hours later (T48), before sacrifice. Voiding behaviour was observed as above for 30 min-
utes, recording the latency to the first micturition, the number of urine spots and the total spot
area to calculate the voided volume (Cavaggioni et al., 2008; Supporting Information S1). The
last day the animals were sacrificed with excess anesthesia (xilazine 60 mg/kg and ketamine
225 mg/kg body weight i.p.) after monitoring the voiding pattern for 30 minutes and the blad-
ders explanted for histological analysis.
Histology
After dissection, the bladders were fixed with 4% (w/v) paraformaldehyde in 0.1 M phosphate
buffer, pH 7.4 (PBS) for one hour at room temperature and then washed with PBS. All the
bladders from the five groups of CYP-treated animals and from an untreated age, sex and
weight-matched group were dehydrated in ethanol, cleared in xylene and then embedded in
paraffin wax. Bladders were cut in 7 μm sections parallel to the equatorial plane. Alternate
bladder sections were stained with routine haematoxylin and eosin to identify the bladder lay-
ers to evaluate its overall morphology and to measure the thickness of the urothelium, or with
bis-benzimide in PBS (1:1000, Sigma) to visualize nuclei [20].
Images (300 dpi) were obtained using a Leica DMR epifluorescence microscope (Leica
Microsystems AG, Wetzlar, Germany) equipped with a Leica DC 100 camera and software,
with a 20x objective (Leica HC PL Fluotar NA: 0.50). The digital images were processed with
Adobe Photoshop CS6 software. Quantitative analysis was performed with ImageJ software. A
microscopic field (20x magnification) was selected from each section (N = 7 to 12 sections per
mouse) within the urothelium, to estimate its thickness. The measurement (μm) was per-
formed from the very basal cellular layer to the apical cellular layer of the urothelium, consider-
ing the measured distance as a line with perpendicular orientation relative to the basal
membrane. For each mouse, at least 15 measurements were selected and averaged, excluding
those made on the most curved area of the urothelium. All the images were analysed by the
same examiner (MJR), who was blind to the experimental group.
Statistical analysis
Data (reported in S1 Data, S2 Data, S3 Data, and S5 Data) are presented as mean±SEM unless
otherwise stated. The validation data were analyzed with t-test (untreated vs. CYP-treated
mice), while the body weight data underwent a bivariate mixed-design ANOVA (Treatment:
control vs. CYP-treated; Day of treatment: day 0, 2, 4, 6), followed by Duncan’s post hoc test.
The latency to the first micturition, the number of drops and the urine volume estimated
from total drop area were analyzed with a bivariate mixed-design ANOVA for the factors
Treatment (saline, imipramine, desipramine, duloxetine and 4-OH duloxetine) and Time (T0:
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before the first antidepressant injection, T24: 24 hours after the first injection, T48: 48 hours
after the first injection), and with Duncan’s post hoc test to compare treated mice to saline
group at the same time point. Since the same time elapsed from the last CYP injection for every
group (saline- or antidepressant-treated), this may represent a better control than values from
the same-group before injection of the drug.
The histology data were analyzed with a monovariate ANOVA (Treatment: No CYP, CYP
followed by: saline, imipramine, desipramine, duloxetine or 4-OH-duoxetine), followed by
Duncan’s post hoc test. The one-side significance level was set at p<0.05.
Results
Validation of the OAB model
The OAB model was tested and validated on CD-1 mice (Fig. 1). A statistically significant reduc-
tion in the first voiding latency, t(10) = 9.297, p<0.0001, and increase in voiding, both number of
spots t(10) = 4.550 p = 0.001 and volume of released urine, t(10) = 2.337 p<0.05, was apparent in
CYP-treated mice, as expected. The mice body weight did not change during the treatment.
Antidepressants revert the CYP-induced increase in urine release
After validation of the CD1mouse OABmodel, the effect of antidepressants was evaluated in 35
OAB-induced mice (Fig. 2). The latency to the first micturition was different according to Time,
F (2, 60) = 24.427, p<0.0001, with a significant increase in latency at each time point (Duncan’s
test, Fig. 2A). In addition, the Treatments were different, F (4,30) = 4.144, p<0.01, since only sa-
line-treated mice showed a significantly shorter latency compared to all the other treatments,
which did not differ among each other. These differences are best explained by the significant in-
teraction Time x Treatment, F (8,60) = 3.680, p<0.002. The post hoc test showed that at T0 the
latencies did not differ among groups. While saline-treated mice did not change their latency to
the first micturition at the three time-points, the administration of imipramine, duloxetine and
4-OH-duloxetine increased latency significantly at T24 and T48, while desipramine increased it
only at T48. The volume of voided urine changed across treatments, F (4,30) = 5.388 p<0.005,
with a significant decrease for imipramine, desipramine, duloxetine and 4-OH-duloxetine com-
pared to saline. It also changed across Time F (2,60) = 9.471, p<0.0005, with a significant de-
crease in volume at T24 and T48 (Duncan’s test, Fig. 2B). The significant Time x Treatment
interaction F(8,60) = 3.249, p<0.005 showed that at T0 the groups did not differ, while desipra-
mine and duloxetine induced a decrease in voided urine already at T24, and all four antidepres-
sants induced a decrease at T48. The number of urine spots differed according to time, F (2,60)
= 38.115, p<0.0001, with more spots at T0 compared to T24 and T48, which did not differ be-
tween each other (Duncan’s test, Fig. 2C). The significant interaction Time x Treatment, F
(8,60) = 2.583, p<0.02, showed that at T0 all groups produced a high yet similar number of
urine spots. Then, the number of spots did not change in saline-treated mice across time, while
it decreased at T24 for desipramine and duloxetine and at T48 for all the four antidepressants.
Therefore, antidepressant-treated groups are characterized by a relevant reduction in voiding
behaviour more evident after 48 hours, by showing an increase in the first void latency and a re-
duction in the number of droplets and in the urine volume in comparison with the control saline
group. The changes in the voiding pattern support a broad efficacy of treatments in OAB.
Histology
Measurements on bladder sections were carried out to evaluate the cyto-architecture of the
mucosa. The staining did not show lymphocytes infiltration in the urothelium or lamina
Antidepressants and Micturition Control
PLOS ONE | DOI:10.1371/journal.pone.0121883 March 26, 2015 4 / 11
Fig 1. Voiding behaviour of CYP-injected mice (n = 7) in comparison with a saline injected group
(n = 5). A, B, C: data describing the micturition pattern: first voiding latency (A), urine volume (B) and number
of urine spots (C). D: body weight during the experiment. E, F: Representative UV images of urinary spots of
a control mouse (E) in comparison with a CYP-treated mouse (F). Data are presented as mean±SEM.
ANOVA and Duncan post hoc test, *: p<0.05, **: p<0.005, ***: p<0.001.
doi:10.1371/journal.pone.0121883.g001
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propria. Moreover, no additional cardinal sign of edema or inflammation was found in
the mucosa layer. Lastly, no necrotic lesion through the bladder wall was found under our
experimental conditions. However, some morphological changes were apparent in the
urothelium (Fig. 3): the thickness of urothelium was different F(5,36) = 5.713, p<0.001
among groups, with all CYP-treated groups having a larger urothelium than the untreated
controls.
Fig 2. Voiding behaviour of CYP-injected mice treated with saline or antidepressants. A, B, C: data describing the micturition pattern: first voiding
latency (A), urine volume (B) and number of urine spots (C). Data are presented as mean+SEM. ANOVA and Duncan post hoc test (comparison with saline
group) *: p<0.05, **: p<0.005, ***: p<0.001. D, E, F, G and H: representative UV images of urinary spots collected 48 hours after the beginning of the
antidepressant treatment: control CYP-injected mouse (D), desipramine (E), imipramine (F) duloxetine (G) and 4-hydroxy-duloxetine-treated mouse (H). The
images show a decrease in voiding behaviour in antidepressant-treated mice.
doi:10.1371/journal.pone.0121883.g002
Antidepressants and Micturition Control
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Discussion
The central nervous system is the site of integration and proper implementation of storage and
voiding reflexes, to coordinate the urinary bladder and urethra contractions [21]. Therefore,
centrally acting drugs may be necessary for proper management of voiding dysfunction [22].
Moreover, decision about switching from storage to voiding is dependent on social context and
is strongly affected by mood [23]. In turn, voiding may affect mood and behavior, in particular
in cases of dysfunction [24]. Consequently, micturition is strictly related to higher functions
and behavioral control, so that urinary incontinence may benefit from treatments, like antide-
pressants, directed to improve not only the bladder function, but also the whole autonomic,
neuromuscular and integrated behavioral control [25]. Animal studies indicate that spontane-
ous bladder activity is high in newborns and old rats [26], suggesting that central control may
become more relevant to overcome spontaneous activity.
Urine storage involves a spinal reflex that activates somatic motoneurons and sympathetic
efferents to the urethra, as well as a central inhibition of voiding. On the contrary, voiding re-
quires a parasympathetic reflex integrated by the pontine micturition center and contextual in-
hibition of somatic and sympathetic activity [27]. The pontine micturition center coordinates
autonomic and somatic activity through the constant inflow of sensory afferents that monitor
Fig 3. Transverse bladder sections stained with hematoxylin and eosin for mucosa thicknessmeasurement. The bladder mucosa (UL: urothelium
layer, LP: lamina propria) and the muscular layer (ML) are shown. Scale bar = 100 μm, 20Xmagnification. A and B: mucosa of a CYP-treated mouse in
contact with the lumen at the top and the entire muscular layer at the bottom. A representative bladder section shows the morphology of the tissue (A) and the
precise area in grey (B) corresponding with the urothelium, where its thickness was measured. C: thickness of the urothelium (μm) plotted across
experimental groups. Control represents bladders of untreated mice, while all the other bars refer to CYP-treated mice, injected with saline or antidepressant.
Data are presented as mean+SEM compared with control group, ANOVA and Duncan post hoc test * p<0.05, ** p<0.005, *** p<0.001, n = 7 for each
experimental group.
doi:10.1371/journal.pone.0121883.g003
Antidepressants and Micturition Control
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bladder filling [28], under the modulating influxes of many neurotransmitter systems [29]. In
both rats and humans the midbrain periacqueductal gray, which receives bladder sensory affer-
ents, may activate the pontine micturition center to induce voiding [30, 31]. Afferents directed
to the periacqueductal gray are subsequently mapped in the insula and monitored by the ante-
rior cingulate gyrus, while the prefrontal cortex is involved in voiding initiation, by relieving its
inhibition to the pontine micturition center [32, 33].
Noradrenaline, serotonin and dopamine are the most important modulatory neurotrans-
mitters of this function.
The rationale for duloxetine use in incontinence relies on the modulatory actions of seroto-
nin and noradrenaline on the neural control centers of the bladder and urethra, located in the
sacral spinal cord, to promote storage and prevent urine leakage, via the contraction of the ex-
ternal urethral sphincter [34], and on the direct centrifugal inhibition exerted by serotonergic
fibers from the raphe nuclei on sensory afferents, resulting in reduced bladder activity [35].
Moreover, poor control of the urinary bladder is associated with insufficient activation of the
orbitofrontal cortex, suggesting a central site for drugs aimed at improving micturition func-
tion [36]. Acute administration of imipramine and desipramine increases the threshold for the
spinal voiding reflex, while chronic administration affects central components [37]. Duloxetine
may help to treat overactive bladder in complex neurologic pathologies, either in the presence
of depression or not [38–40].
In order to elucidate the complex effect of pharmacologically active molecules, it is neces-
sary to use animal models that closely match the characteristics of the human disease. Micturi-
tion disorders were mostly studied in acute animal models, the most common model being the
birth trauma, which refers to an acute event [41]. However, in adult humans overactive bladder
develops as a consequence of chronic conditions and rarely involves selected nerve lesions. A
single chronic OAB mouse model was developed [12]: we refined it to evaluate the effect of an-
tidepressant agents. Our data show that it is possible to induce a model of OAB also in outbred
CD-1 mice. These may represent a cost-effective choice, compared to the inbred C57 strain
originally used. In addition, the micturition behaviour for CD-1 mice is well known, since this
strain is currently used for behavioural studies on urine countermarking [13, 14]. Moreover,
the behavioural phenotype of CD-1 mice as a model for depression has been described [42].
The present OAB protocol does not interfere with major determinants of normal behaviour,
therefore it allows the sensitive detection of modifications related to the micturition behaviour.
Lastly, it allows the recognition of morphological changes across the bladder layers, since it
causes no major tissue damage.
Our data show that 40 mg/kg CYP dosage was effective in the induction of OAB condition
in CD-1 mouse strain, while a higher dosage is currently employed for mimicking bladder pain
syndrome [43]. Body weight, behavioural assessment and histology confirmed that CYP injec-
tion was without relevant side effects, as previously reported for C57/Bl6J mice [12]. After 48
hours, each of the four pharmacologically active agents was able to relieve signs of urgency, as
demonstrated by increased latency to the first micturition and decreased spots number and
volume of released urine. Only minor differences were detected between the molecules, in par-
ticular on the time-course of their effects. No difference was present on the magnitude of the
effects 48 hours after the beginning of the treatment. These data suggest that the possible scale-
down of dosage would permit the appearance of variations in the efficacy of the treatment, as
well as prolonged treatments, as it happens for human patients, would allow the emergence of
a more complete picture of the peripheral and central effects.
Given the complex central and peripheral effects of antidepressant molecules on micturi-
tion, the present results could be complemented by studies aimed at elucidating central action
Antidepressants and Micturition Control
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of antidepressant on micturition control, to gain knowledge that may improve their clinical use
beyond their antidepressant activity.
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S2 Data. Raw data for Fig. 2.
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S3 Data. Raw data for Fig. 3.
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S4 Data. Raw data for S1 Fig.
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S1 Fig. Calibration curve used to calculate the volume of voided urine. Different volumes of
male mouse urine (from 1 to 750 microliters) were spotted on the Benchguard paper sheet
(the same type used for urine drop analysis) and processed in the same way: they were left for
48 hours at room temperature, then UV transilluminated and photographed. The total num-
ber of pixels within urine spots was calculated with ImageJ software, then converted into vol-
ume of voided urine according to the equation: y = 445.39x + 2710.3. This gives a linear fit
R2 = 0.9964, according to the calibration curve.
(PDF)
S2 Fig. Experimental layout.Mice were injected with CYP (40 mg/kg), one injection every 48
hours, for four times. 24 hours after the last CYP injection mice were tested for micturition
(T0) and then were given a control (saline) or antidepressant injection (see text for dosages).
24 hours later, they were tested again (T24) and then were given the second injection. After ad-
ditional 24 hours, they were tested for micturition behavior for the third time (T48).
(PDF)
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